TREATMENT OUTCOMES AND EARLY RESPONSE PREDICTORS IN PEDIATRIC HIGH GRADE B- CELL NON-HODGKIN LYMPHOMA TREATED WITH REDUCED-INTENSITY RITUXIMAB-BASED CHEMOTHERAPY (SIOP 2026) - Oct 23, 2026 - Abstract #Shift 02 - 173; Pres time: Sep 17, 2026; Location: Exhibition Area; "Survival outcomes were comparable to those reported from other low-middle-income countries with minimal toxicity. Early post-prephase and post-induction responses were key prognostic markers; post-induction CR predicted favorable outcomes and may obviate need of repeat PET-CT post consolidation,while non-CR identified high-risk patients requiring treatment intensification."
Clinical • B Cell Non-Hodgkin Lymphoma • Burkitt Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin's Lymphoma • Pediatrics
|
|
Helie Raval1; Dale Montes2; Maharshi Trivedi2; Dipesh Dave2; Parth Paraliya2; Chinmay Doctor2; Harsha Panchal2
|